Pharmacodynamic effect of prasugrel 5 mg vs clopidogrel 150 mg in elderly patients with high on-clopidogrel platelet reactivity

American Heart Journal

Volumn 165, Issue 1, 2013, Pages 73-79

  Alexopoulos, Dimitrios ^a   Xanthopoulou, Ioanna ^a   Plakomyti, Theodora Eleni ^a   Theodoropoulos, Konstantinos C ^a   Mavronasiou, Eleni ^a   Damelou, Anastasia ^a   Hahalis, George ^a   Davlouros, Periklis ^a  

^a UNIVERSITY HOSPITAL OF PATRAS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; PRASUGREL;

ACUTE CORONARY SYNDROME; AGED; ANGINA PECTORIS; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; DRUG MEGADOSE; HUMAN; LOW DRUG DOSE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; TREATMENT DURATION;

ACUTE CORONARY SYNDROME; AGED; FEMALE; HUMANS; MALE; PERCUTANEOUS CORONARY INTERVENTION; PIPERAZINES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PROSPECTIVE STUDIES; THIOPHENES; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84870889868     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2012.10.008     Document Type: Article

References (30)

1. K.P. Alexander, L.K. Newby, and C.P. Cannon Acute coronary care in the elderly, part I: non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology Circulation 115 19 2007 2549 2569
2. K.P. Alexander, L.K. Newby, and P.W. Armstrong Acute coronary care in the elderly, part II: ST-segment-elevation myocardial infarction: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology Circulation 115 19 2007 2570 2589
3. A. Avezum, M. Makdisse, and F. Spencer Impact of age on management and outcome of acute coronary syndrome: observations from the Global Registry of Acute Coronary Events (GRACE) Am Heart J 149 1 2005 67 73
4. S.D. Wiviott, E. Braunwald, and C.H. McCabe TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 20 2007 2001 2015
5. R.E. Wrishko, C.S. Ernest, and D.S. Small Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38 J Clin Pharmacol 49 8 2009 984 998
6. S.D. Wiviott, E.M. Antman, and E. Braunwald Prasugrel Circulation 122 4 2010 394 403
7. United States Food and Drug Administration. FDA approved drug products, 2009. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm? fuseaction-Search.DrugDetails. Last accessed 1 June 2012.
8. European Medicines Agency Evaluation of Medicines for Human Use Doc. Ref.:EMEA/117561/2009. http://www.ema.europa.eu/docs/en-GB/document-library/ EPARPublicassessmentreport/human/000984/WC500021975.pdf. Last accessed 1 June 2012.
9. S.S. Brar, J. Ten Berg, and R. Marcucci Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention a collaborative meta-analysis of individual participant data J Am Coll Cardiol 58 19 2011 1945 1954
10. D.J. Angiolillo, J.F. Saucedo, and R. Deraad SWAP Investigators. Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study J Am Coll Cardiol 56 13 2010 1017 1023
11. D. Alexopoulos, G. Dimitropoulos, and P. Davlouros Prasugrel overcomes high on-clopidogrel platelet reactivity post stenting more effectively than high dose (150 mg) clopidogrel: the importance of CYP2C19*2 genotyping J Am Coll Cardiol Intv 4 4 2011 403 410
12. D. Alexopoulos, I. Xanthopoulou, and P. Davlouros Prasugrel overcomes high on-clopidogrel platelet reactivity in chronic coronary artery disease patients more effectively than high dose (150 mg) clopidogrel Am Heart J 162 4 2011 733 739
13. T. Cuisset, J. Quilici, and C. Grosdidier Comparison of platelet reactivity and clopidogrel response in patients ≤75 years versus >75 years undergoing percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome Am J Cardiol 108 10 2011 1411 1416
14. T. Gremmel, S. Steiner, and D. Seidinger Adenosine diphosphate-inducible platelet reactivity shows a pronounced age dependency in the initial phase of antiplatelet therapy with clopidogrel J Thromb Haemost 8 1 2010 37 42
15. J. Silvain, G. Cayla, and J.S. Hulot High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study Eur Heart J 33 10 2012 1241 1249
16. N.J. Breet, H.E. van Donkersgoed, and J.W. van Werkum Is platelet inhibition due to thienopyridines increased in elderly patients, in patients with previous stroke and patients with low body weight as a possible explanation of an increased bleeding risk? Neth Heart J 19 6 2011 279 284
17. D. Capodanno, and D.J. Angiolillo Antithrombotic therapy in the elderly J Am Coll Cardiol 56 21 2010 1683 1692
18. P. Capranzano, C. Tamburino, and D. Capodanno Platelet function profiles in the elderly: Results of a pharmacodynamic study in patients on clopidogrel therapy and effects of switching to prasugrel 5 mg in patients with high platelet reactivity Thromb Haemost 106 6 2011 1149 1157
19. M.J. Price, D.J. Angiolillo, and P.S. Teirstein Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the gauging responsiveness with a VerifyNow P2Y12 assay: impact on thrombosis and safety (GRAVITAS) trial Circulation 124 10 2011 1132 1137
20. G. Campo, G. Parrinello, and P. Ferraresi Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome J Am Coll Cardiol 57 25 2011 2474 2483
21. P. Htun, S. Fateh-Moghadam, and C. Bischofs Low responsiveness to clopidogrel increases risk among CKD patients undergoing coronary intervention J Am Soc Nephrol 22 4 2011 627 633
22. J.S. Riesmeyer, D.E. Salazar, and G.J. Weerakkody Relationship between exposure to prasugrel active metabolite and clinical outcomes in the TRITON-TIMI 38 substudy J Clin Pharmacol 52 6 2012 789 797
23. G. Parodi, B. Bellandi, and F. Venditti Residual platelet reactivity, bleedings, and adherence to treatment in patients having coronary stent implantation treated with prasugrel Am J Cardiol 109 2 2012 214 218
24. D. Alexopoulos Prasugrel resistance: fact or fiction Platelets 23 2 2012 83 90
25. P.A. Gurbel, E.M. Ohman, and Y.H. Jeong Toward a therapeutic window for antiplatelet therapy in the elderly Eur Heart J 33 10 2012 1187 1189
26. Comparison of Prasugrel and Clopidogrel in Very Elderly and Non-Elderly Patients With Stable Coronary Artery Disease (GENERATIONS). US National Library of Medicine. ClinicalTrials.gov [online]. http://clinicaltrials.gov/ct2/show/ NCT01107912. Accessed June 3, 2012.
27. C.T. Chin, M.T. Roe, and K.A. Fox TRILOGY ACS Steering Committee. Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial Am Heart J 160 1 2010 16 22.e1
28. L. Wallentin, R.C. Becker, and A. Budaj Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 11 2009 1045 1057
29. G. Kassimis, P. Davlouros, and I. Xanthopoulou CYP2C19*2 and other genetic variants affecting platelet response to clopidogrel in patients undergoing percutaneous coronary intervention Thromb Res 129 4 2012 441 446
30. J.L. Mega, W. Hochholzer, and A.L. Frelinger 3rd Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease JAMA 306 20 2011 2221 2228